Ritipenem
Chemical compound
- 84845-57-8 Y
- 65633
- 59074
- D4SL77931L
- ChEMBL70088
- DTXSID60868840
- Interactive image
- C[C@@H](O)[C@@H]1[C@H]2SC(=C(N2C1=O)C(=O)O)COC(=O)N
InChI
- InChI=1S/C10H12N2O6S/c1-3(13)5-7(14)12-6(9(15)16)4(19-8(5)12)2-18-10(11)17/h3,5,8,13H,2H2,1H3,(H2,11,17)(H,15,16)/t3-,5+,8-/m1/s1
- Key:IKQNRQOUOZJHTR-UWBRJAPDSA-N
Ritipenem is a penem class antimicrobial agent. Ritipenem is manufactured by Tanabe Seiyaku in the ritipenem acoxil prodrug form, which can be taken orally . It is not FDA approved in the United States as of 2008.
References
- Eiland III EH, Gatlin D (October 2008). "Forecast of antibiotic development in an era of increasing bacterial resistance". Journal of Pharmacy Practice. 21 (5): 313–8. doi:10.1177/0897190008318499. S2CID 71894409.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e